Clinical Trials Logo

Clinical Trial Summary

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.


Clinical Trial Description

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache. Excluded populations include those with sickle cell, concern for CNS infection ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03984045
Study type Interventional
Source Newark Beth Israel Medical Center
Contact Adam Sivitz, MD
Phone 973 926 2484
Email adam.sivitz@rwjbh.org
Status Recruiting
Phase Phase 3
Start date June 6, 2019
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06068751 - Aerobic Exercise and Neck Exercises in Pediatric Migraine Treatment N/A
Terminated NCT03885154 - Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine Phase 2
Recruiting NCT05814497 - Supraspinal Processing of Sensory Aspects of Pain N/A
Not yet recruiting NCT06277063 - nVNS for the Prevention and Treatment of Primary Headache N/A
Recruiting NCT06182098 - Intravenous Fluids in Pediatric Migraine N/A
Completed NCT03806595 - A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine Phase 1
Completed NCT04968093 - Mindfulness for Adolescents for CM and HFEM N/A
Withdrawn NCT04466826 - Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients Phase 2
Recruiting NCT05969990 - Tryptophan Metabolites in Pediatric Migraine
Not yet recruiting NCT06180577 - A Survey Study to Assess the Accessibility of the Nerivio Device at School
Completed NCT04537429 - A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab Phase 1